Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Ciscom Corp. Strengthens Its Board of Directors with Addition of Two Experienced Industry Leaders (click to learn more) Silver North Options GDR Silver Project, Silvertip-Midway District, Yukon (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kezar Life Sciences Inc KZR

Healthcare Biotechnology
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical... see more

Recent & Breaking News (NDAQ:KZR)

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire April 5, 2023

Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

Business Wire March 14, 2023

Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023

Business Wire March 13, 2023

Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023

Business Wire March 6, 2023

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire March 3, 2023

Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference

Business Wire March 1, 2023

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire February 6, 2023

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire January 13, 2023

Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Business Wire January 4, 2023

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire December 7, 2022

Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022

Business Wire November 14, 2022

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Business Wire November 11, 2022

Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Business Wire November 10, 2022

Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

Business Wire November 9, 2022

Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN's Kidney Week 2022 Annual Meeting

Business Wire November 3, 2022

Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology's Kidney Week 2022 Annual Meeting

Business Wire October 14, 2022

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Business Wire October 6, 2022

Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis

Business Wire October 3, 2022

Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022

Business Wire September 29, 2022

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Business Wire September 2, 2022